drugset / Trial / NCT02906683
Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.
Timeline
- Start
- 2016-10-20
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
Outcome
Missed primary endpoint
registry analysis (superiority test); TAS-303 3 mg vs Placebo; p = 0.329 NCT02906683 ↗
registry analysis (superiority test); TAS-303 6 mg vs Placebo; p = 0.285 NCT02906683 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PARENT OF TAS-303 | Small molecule | 3 mg | Oral |
| Subject | PARENT OF TAS-303 | Small molecule | 6 mg | Oral |